MHRA
- Status: likely_approved
🇬🇧 Lynparza in United Kingdom
NICE has issued 8 UK HTA decisions
Marketing authorisation
Health technology assessment
8 decisions from NICE for Lynparza in United Kingdom.
NICE TA1040 — ✓ Recommended
- Indication assessed: treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
NICE recommended Lynparza for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy. This decision was made without a Patient Access Scheme, but a commercial arrangement was in place. The restriction text for this decision is not specified.
NICE TA951 — ✓ Recommended
- Indication assessed: untreated hormone-relapsed metastatic prostate cancer
NICE recommended Lynparza for the treatment of untreated hormone-relapsed metastatic prostate cancer. This decision was made based on a commercial arrangement, indicating that a price was agreed upon between the manufacturer and the NHS. No restrictions or conditions were placed on the use of Lynparza for this indication.
NICE TA962 — ✓ Recommended
- Indication assessed: maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
NICE recommended Lynparza for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. This decision was made based on a commercial arrangement. No restriction or condition was applied to the recommendation.
NICE TA946 — ✓ Recommended
- Indication assessed: maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
NICE recommended Lynparza for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. This decision was made based on a commercial arrangement. No restriction or condition was applied to the recommendation.
NICE TA908 — ✓ Recommended
- Indication assessed: maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
NICE recommended Lynparza for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer. This decision was made for patients who have had 2 or more courses of platinum-based chemotherapy. The recommendation was made with a commercial arrangement in place, but no Patient Access Scheme was negotiated.
NICE TA886 — ✓ Recommended
- Indication assessed: adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
NICE recommended Lynparza for the adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy. This decision was made based on a commercial arrangement, indicating that the cost of the treatment was negotiated between the manufacturer and the NHS. There are no restrictions on the use of Lynparza for this indication.
NICE TA887 — ✓ Recommended
- Indication assessed: previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
NICE recommended Lynparza for the treatment of previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. This decision was made based on the drug's clinical effectiveness and cost. A commercial arrangement was in place, but details of the cost basis are not provided.
NICE TA750 — — Appraisal terminated
- Indication assessed: maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)
NICE made a decision to terminate the appraisal of Lynparza for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer. This decision means that NICE will not make a recommendation on the use of Lynparza for this indication. The decision was made without a cost basis being reported, as the ICER was not provided. There were no restrictions or conditions placed on the use of Lynparza.
Lynparza in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Lynparza approved in United Kingdom?
Yes. MHRA has authorised it.
Who is the marketing authorisation holder for Lynparza in United Kingdom?
AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.
Has Lynparza been assessed by UK health technology agencies?
Yes — 8 UK HTA decisions on record from NICE.